Company sets sights on becoming one of top three insulin manufacturers in world
Julphar has signed an agreement with leading global medical technology company, BD (Becton, Dickinson and Company), to supply disposable insulin pens in the UAE.
Through this agreement, Julphar’s human insulin formulations will be available for administration through BD’s portfolio of BD Vystra disposable pens.
Commenting on the announcement, Jerome Carle, General Manager of Julphar, said: “Through our agreement with BD, we will be able to keep pace with the growth and further improve our position in this lucrative market placing us among the top three players in the world.”
Insulin pens are small, disposable, lightweight plastic handheld devices containing prefilled insulin cartridges that are convenient and more versatile than some traditional methods for insulin injection.
Julphar launched its $150m biopharmaceutical facility in 2012, which has the capacity to produce 1,500kg of recombinant human insulin and insulin analogues crystals (rDNA), equivalent to a combination of 30 million vials and 25 million cartridges and pens of insulin annually.
